샘플 요청 목록

 카트 문의
시장보고서
상품코드
1551665

단백뇨 치료제 시장

Proteinuria Therapeutics
발행일: | 리서치사: 구분자 Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 199 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 8,874,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 26,623,000
카드담기
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 단백뇨 치료제 시장은 2030년까지 26억 달러에 달할 전망

세계의 단백뇨 치료제 시장은 2023년에 18억 달러로 평가되었고, 분석 기간 2023년부터 2030년까지 CAGR 5.2%로 성장할 전망이며, 2030년에는 26억 달러에 이를 것으로 예측됩니다. 안지오텐신 전환 효소(ACE) 억제제는 본 보고서에서 분석한 부문 중 하나이며 CAGR은 7.8%로 성장을 지속하고, 분석 기간 종료 시 9억 4,920만 달러에 달할 것으로 예측됩니다. 안지오텐신 수용체 차단제(arbs) 분절의 성장률은 분석 기간 동안 CAGR 5.0%로 추정됩니다.

미국 시장은 5억 220만 달러로 추정, 중국은 CAGR 9.0%로 성장할 것으로 예측

미국의 단백뇨 치료제 시장은 2023년 5억 220만 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 5억 6,690만 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 9.0%로 전망됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.9%와 5.5%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 3.2%로 성장할 것으로 예측됩니다.

세계의 단백뇨 치료제 시장-주요 동향 및 촉진요인 요약

단백뇨란 무엇이며 왜 그 치료가 중요한가?

소변에 비정상적인 양의 단백질이 존재하는 단백질 소변은 신장 장애의 중요한 지표이며, 종종 만성 신장 질환(CKD)의 경고 표시 역할을 합니다. CKD는 사구체로 알려진 신장 여과 장치가 손상되어 혈액에서 단백질을 유지할 수 없으며 소변에서 단백질이 누출되어 발생합니다. 치료되지 않은 단백질은 신장 질환의 진행을 가속화하고 신장 기능 장애를 추가로 진행시켜 투석과 신장 이식이 필요할 수 있습니다. 단백뇨는 신장 질환의 마커일 뿐만 아니라 심혈관 사건의 위험 인자이기 때문에 관리는 환자의 QOL에 큰 영향을 미치는 합병증을 예방하는 데 매우 중요합니다. 치료는 일반적으로 당뇨병과 고혈압과 같은 기초 질환을 조절하는 데 중점을 두고 단백질 누출을 줄이고 신장 장애의 진행을 늦추는 치료법을 사용합니다.

누가 단백뇨 치료제를 필요로 하는가?

단백뇨 치료제는 만성 신장 질환, 당뇨병, 고혈압, 사구체 신염으로 진단받은 환자에게 특히 중요합니다. 이러한 치료제는 단백질 누출을 일으키는 근본적인 메커니즘을 다루어 신장 기능을 보호하고 심각한 합병증의 위험을 줄이기 위해 필수적입니다. 안지오텐신 전환 효소(ACE) 억제제와 안지오텐신 II 수용체 길항제(ARB)는 혈압을 낮추고 단백질 배설을 줄이기 때문에 단백뇨 관리에 잘 처방됩니다. 게다가 나트륨-글루코스 공수송체-2(SGLT2) 억제제와 같은 새로운 약물 클래스별은 단백뇨를 감소시킬 뿐만 아니라 심혈관에 대한 효과도 기대되고 있으며, 치료제로서 중요한 위치를 차지합니다. 단백뇨 치료의 목표는 증상을 관리하는 것뿐만 아니라 신장 질환의 진행을 늦추거나 예방하는 것입니다.

단백뇨 치료제의 최신 동향 및 혁신이란?

단백뇨 치료제 분야에서는 보다 효과적이고 대상적인 치료의 개발에 초점을 맞춘 연구가 진행되고 있으며, 큰 진보를 볼 수 있습니다. 가장 주목할 만한 동향 중 하나는 엔도 세린 수용체 길항제 및 미네랄 코르티코이드 수용체 길항제와 같은 새로운 약물 클래스별 연구이며, 단백뇨를 감소시키고 신장 기능을 보호하는 새로운 작용기전을 제공합니다. 또한 기존의 ACE 억제제와 ARB와 SGLT2 억제제와 파인레논 등의 신약을 통합하여 단백뇨와 관련 위험을 종합적으로 관리하는 것을 목적으로 하는 병용요법에 대한 관심도 높아지고 있습니다. 정밀의료도 이 분야에 진출하고 있으며, 치료 효과를 높이고 부작용을 최소화하기 위해 유전자와 바이오마커프로파일에 따라 치료법을 조정하고 있습니다. 게다가 비침습적 모니터링 기술의 진보로 단백뇨 수준을 보다 정확하게 평가할 수 있게 되어, 보다 좋은 질환 관리와 시기 적절한 치료 조정이 가능해지고 있습니다. 이러한 혁신은 단백뇨 치료제의 진화를 촉진하고 신장병 환자의 예후 개선에 희망을 가져왔습니다.

단백뇨 치료제 시장의 성장 촉진요인은?

단백뇨 치료제 시장의 성장은 만성 신장 질환 및 관련 질병의 세계 유병률 증가를 반영하는 여러 요인에 의해 견인되고 있습니다. 주요 요인은 당뇨병과 고혈압 이환율 증가를 포함하며, 이는 단백뇨의 발병에 크게 기여합니다. 이러한 병태가 특히 고령화된 인구 집단과 신흥 시장에서 더욱 확산됨에 따라 효과적인 단백뇨 치료제에 대한 수요가 높아질 것으로 예상됩니다. 약물 개발의 기술적 진보, 특히 새로운 치료 클래스와 병용 치료의 도입은 더욱 효과적인 치료 옵션을 제공함으로써 시장 성장을 가속하고 있습니다. 신장 질환의 조기 진단과 조기 관리에 대한 주목 증가는 건강 관리 제공업체가 신장 장애의 진행을 예방하려고 노력하여 단백뇨 치료제의 채택을 더욱 가속화하고 있습니다. 또한, 단백뇨 및 심혈관 위험의 연관성에 대한 인식 증가는 신장과 심혈관 모두의 건강을 관리하는 이중 이점을 제공하는 치료에 대한 수요를 촉진하고 있습니다. 이러한 요인이 현재 진행중인 연구개발과 함께 단백뇨 치료제 시장의 확대에 박차를 가하고 있습니다.

조사 대상 기업 예(전 49건)

  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Calliditas Therapeutics AB
  • Certa Therapeutics
  • Everest Medicines
  • Ionis Pharmaceuticals, Inc.
  • Ligand Pharmaceuticals, Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Travere Therapeutics
  • Vertex Pharmaceuticals Inc.
  • Walden Biosciences, Inc.
  • ZyVersa Therapeutics, Inc.;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.10.04

Global Proteinuria Therapeutics Market to Reach US$2.6 Billion by 2030

The global market for Proteinuria Therapeutics estimated at US$1.8 Billion in the year 2023, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. Angiotensin-converting Enzyme (ACE) Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$949.2 Million by the end of the analysis period. Growth in the Angiotensin Receptor Blockers (arbs) segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$502.2 Million While China is Forecast to Grow at 9.0% CAGR

The Proteinuria Therapeutics market in the U.S. is estimated at US$502.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$566.9 Million by the year 2030 trailing a CAGR of 9.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Proteinuria Therapeutics Market - Key Trends and Drivers Summarized

What Is Proteinuria and Why Is Its Treatment So Critical?

Proteinuria, characterized by the presence of abnormal amounts of protein in the urine, is a key indicator of kidney damage and often serves as a warning sign for chronic kidney disease (CKD). The condition arises when the kidneys' filtering units, known as glomeruli, are damaged and cannot retain proteins in the bloodstream, leading to their leakage into the urine. Untreated proteinuria can accelerate the progression of kidney disease, leading to further renal dysfunction and potentially necessitating dialysis or kidney transplantation. Proteinuria is not only a marker of kidney disease but also a risk factor for cardiovascular events, making its management crucial for preventing complications that can significantly impact a patient's quality of life. Treatment typically focuses on controlling underlying conditions such as diabetes and hypertension, using therapies that reduce protein leakage and slow kidney damage progression.

Who Needs Proteinuria Therapeutics and Why Are They So Essential?

Proteinuria therapeutics are particularly vital for patients diagnosed with chronic kidney disease, diabetes, hypertension, and glomerulonephritis—conditions that often lead to or exacerbate proteinuria. These therapies are essential because they address the underlying mechanisms that cause protein leakage, thereby protecting kidney function and reducing the risk of severe complications. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are commonly prescribed to manage proteinuria, as they help lower blood pressure and reduce protein excretion. Additionally, newer classes of drugs, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, have shown promise in not only reducing proteinuria but also providing cardiovascular benefits, making them an important addition to the therapeutic arsenal. The goal of proteinuria treatment is not only to manage symptoms but to delay or prevent the progression of kidney disease, making these therapies a cornerstone of renal care.

What Are the Latest Trends and Innovations in Proteinuria Therapeutics?

The field of proteinuria therapeutics has witnessed significant advancements, with ongoing research focused on developing more effective and targeted treatments. One of the most notable trends is the exploration of novel drug classes, such as endothelin receptor antagonists and mineralocorticoid receptor antagonists, which offer new mechanisms of action for reducing proteinuria and protecting kidney function. Additionally, there is growing interest in combination therapies that integrate traditional ACE inhibitors or ARBs with newer agents like SGLT2 inhibitors or finerenone, aiming to provide comprehensive management of proteinuria and its associated risks. Precision medicine is also making inroads in this field, with therapies being tailored based on genetic and biomarker profiles to enhance treatment efficacy and minimize adverse effects. Furthermore, advances in non-invasive monitoring technologies are enabling more accurate assessment of proteinuria levels, allowing for better disease management and timely therapeutic adjustments. These innovations are driving the evolution of proteinuria therapeutics, offering hope for improved outcomes for patients with kidney disease.

What Is Driving the Growth of the Proteinuria Therapeutics Market?

The growth in the proteinuria therapeutics market is driven by several factors that reflect the increasing prevalence of chronic kidney disease and related conditions globally. A primary driver is the rising incidence of diabetes and hypertension, which are major contributors to the development of proteinuria. As these conditions become more widespread, particularly in aging populations and emerging markets, the demand for effective proteinuria therapies is expected to rise. Technological advancements in drug development, particularly the introduction of novel therapeutic classes and combination therapies, are also propelling market growth by offering more effective treatment options. The increasing focus on early diagnosis and management of kidney disease is further accelerating the adoption of proteinuria therapeutics, as healthcare providers seek to prevent the progression of kidney damage. Additionally, the growing awareness of the link between proteinuria and cardiovascular risk is driving demand for treatments that offer dual benefits in managing both renal and cardiovascular health. These factors, coupled with ongoing research and development efforts, are fueling the expansion of the proteinuria therapeutics market.

Select Competitors (Total 49 Featured) -

  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Calliditas Therapeutics AB
  • Certa Therapeutics
  • Everest Medicines
  • Ionis Pharmaceuticals, Inc.
  • Ligand Pharmaceuticals, Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Travere Therapeutics
  • Vertex Pharmaceuticals Inc.
  • Walden Biosciences, Inc.
  • ZyVersa Therapeutics, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Proteinuria Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Kidney Disease Propels Growth in Proteinuria Therapeutics Market
    • Increasing Incidence of Diabetes and Hypertension Drives Adoption of Proteinuria Therapies
    • Advancements in Drug Development Strengthen Business Case for Novel Proteinuria Treatments
    • Expanding Research in Nephrology Expands Addressable Market Opportunity for Proteinuria Therapeutics
    • Growing Focus on Cardiovascular Risk Management Generates Demand for Integrated Therapies
    • Innovations in Biomarker-Based Diagnosis Sustain Growth in Proteinuria Therapeutics Market
    • Shift Towards Personalized Medicine Expands Market Potential for Targeted Proteinuria Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Proteinuria Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Proteinuria Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Proteinuria Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Angiotensin-converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Angiotensin-converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Angiotensin-converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Angiotensin Receptor Blockers (arbs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Angiotensin Receptor Blockers (arbs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Angiotensin Receptor Blockers (arbs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Dipeptidyl Peptidase (DPP) IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Dipeptidyl Peptidase (DPP) IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Dipeptidyl Peptidase (DPP) IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Aldosterone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Aldosterone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Aldosterone Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: China 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Proteinuria Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Proteinuria Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: France 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 53: Spain Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Spain Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Spain 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Russia Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Russia 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Rest of Europe Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Rest of Europe 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Proteinuria Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Proteinuria Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 68: Australia Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Australia Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Australia 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 71: India Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: India Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: India 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 74: South Korea Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: South Korea Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: South Korea 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Asia-Pacific Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Asia-Pacific 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Proteinuria Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Proteinuria Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 86: Argentina Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Argentina Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Argentina 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 89: Brazil Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Brazil Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Brazil 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 92: Mexico Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Mexico Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Mexico 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Latin America Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Latin America 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Proteinuria Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Proteinuria Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 104: Iran Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Iran Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Iran 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 107: Israel Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Israel Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Israel 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Saudi Arabia Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Saudi Arabia 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 113: UAE Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UAE Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UAE 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Middle East Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Middle East 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 119: Africa Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Africa Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Africa 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기